Head-to-head comparison of [18F]-fluorodeoxyglucose and [18F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series

Head-to-head comparison of [18F]-fluorodeoxyglucose and [18F]-fluorocholine positron emission tomography/computed tomography in three patients with rare gestational trophoblastic neoplasms: A case series

We report the efficacy of dual positron emission tomography/computed tomography (PET/CT) imaging with [18F]-2'-fluoro-2'-deoxy-D-glucose ([18F]-FDG) and [18F]-fluorocholine ([18F]-FCH) in patients with gestational trophoblastic neoplasia (GTN) for primary diagnosis and staging of this rare...

Full description

Saved in:
Bibliographic Details
Main Authors: Tanyaluck Thientunyakit, Thonnapong Thongpraparn, Tossaporn Siriprapa, Juri G. Gelovani
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-01-01
Series:World Journal of Nuclear Medicine
Subjects:
[18f]-2'-fluoro-2'-deoxy-d-glucose
[18f]-fluorocholine
choriocarcinoma
gestational trophoblastic neoplasia
positron emission tomography/computed tomography
Online Access:http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_91_18
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the efficacy of dual positron emission tomography/computed tomography (PET/CT) imaging with [18F]-2'-fluoro-2'-deoxy-D-glucose ([18F]-FDG) and [18F]-fluorocholine ([18F]-FCH) in patients with gestational trophoblastic neoplasia (GTN) for primary diagnosis and staging of this rare pregnancy-related disorder. Whole-body PET/CT with [18F]-FDG and [18F]-FCH was performed in three patients with GTN in 2 consecutive days. Each detectable lesion was characterized by visual and quantitative analyses. As compared to CT alone, PET/CT with [18F]-FDG and [18F]-FCH PET/CT revealed more hypermetabolic metastatic lesions in the body, but not in the brain. The standard uptake value of [18F]-FDG was generally higher than [18F]-FCH in all detectable tumor lesions. In conclusion, both [18F]-FDG and [18F]-FCH PET/CT can be used for diagnosis and staging for GTN, based on their sensitivity for small extracerebral metastatic lesions. Additional studies are warranted to determine whether the PET/CT imaging with [18F]-FDG and [18F]-FCH can serve as a biomarker of GTN aggressiveness, for prediction of treatment response.
ISSN:1450-1147
1607-3312

Similar Items